Alpha Tau to Participate in Sidoti Small-Cap Conference
JERUSALEM, November 29, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- 5 days ago
Alpha DaRT Advanced Pancreatic Cancer Trial : Highly Promising Interim Results
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no...
- Nov 20
ATM submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT for Recurrent Head & Neck Cancer
Jerusalem, November 20, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative...
- Nov 19
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside...
- Nov 1
Alpha Tau to Participate in November Investor Conferences
JERUSALEM, November 1, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
- Oct 30
ATM Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
JERUSALEM, October 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
- Oct 24
Former U.S. Commissioner of FDA Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
JERUSALEM, October 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
- Sep 14
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Hadassah Medical Center
JERUSALEM, Sept. 14, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
- Aug 29
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR,...
- Aug 24
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
bottom of page